SCHEMBL2115626

SCHEMBL2115626

Cc1ccc2nc(NN)sc2c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 12/20 0.65
RAB9A P51151 12/20 0.65
SMN1; SMN2 Q16637 7/20 0.65
MAPT P10636 6/20 0.65
KDM4E B2RXH2 6/20 0.65
ALDH1A1 P00352 6/20 0.65
MEN1 O00255 5/20 0.65
KMT2A Q03164 5/20 0.65
LMNA P02545 3/20 0.65
TDP1 Q9NUW8 3/20 0.65
ALOX12 P18054 2/20 0.65
GAA P10253 2/20 0.65
HTT P42858 2/20 0.65
PKM P14618 1/20 0.65
MAPK1 P28482 1/20 0.65
GFER P55789 1/20 0.65
DYRK1A Q13627 1/20 0.62
IDO1 P14902 2/20 0.58
TP53 P04637 3/20 0.54
ACP1 P24666 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2138878 0.86 IDO1 (0.65) NPC1RAB9ASMN1; SMN2MAPTKDM4E
SCHEMBL13151088 0.84 NPC1 (0.64) NPC1RAB9ASMN1; SMN2MAPTKDM4E
SCHEMBL21914837 0.82 NPC1 (0.62) NPC1RAB9ASMN1; SMN2MAPTKDM4E
SCHEMBL25322650 0.81 SMN1; SMN2 (0.64) NPC1RAB9ASMN1; SMN2MAPTKDM4E
SCHEMBL8019525 0.79 NPC1 (0.59) NPC1RAB9ASMN1; SMN2MAPTKDM4E
SCHEMBL14184989 0.79 NPC1 (0.59) NPC1RAB9ASMN1; SMN2MAPTKDM4E
SCHEMBL18058957 0.79 NPC1 (0.59) NPC1RAB9ASMN1; SMN2MAPTKDM4E
SCHEMBL11265618 0.79 NPC1 (0.71) NPC1RAB9ASMN1; SMN2MAPTMEN1
SCHEMBL13486495 0.79 DYRK1A (0.76) NPC1RAB9ASMN1; SMN2MAPTKDM4E
SCHEMBL22467930 0.79 DYRK1A (0.67) NPC1RAB9ASMN1; SMN2MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160175303-A1 SYNTHESIS OF NEW BENZOTHIAZOLE DERIVATIVES AS POTENTIAL ANTI-TUBERCULAR AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2016-06-23 US claimed
US-20120095021-A1 SYNTHSIS OF NEW BENZOTHIAZOLE DERIVATIVES AS POTENTIAL ANTI-TUBERCULAR AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH 2012-04-19 US claimed
US-20030072725-A1 Topical cosmetic agents containing 2-hydrazino-1,3 -heteroazoles HAARMANN & REIMER GMBH (DE) 2003-04-17 US claimed
US-20020128268-A1 Use of 2-hydrazino-1,3-thiazoles as antioxidants HAARMANN & REIMER GMBH (DE) 2002-09-12 US claimed
CN-118702646-A Novel polymerizable liquid crystal 罗利克技术有限公司 2024-09-27 CN disclosed
CN-114026078-B Novel polymerizable liquid crystal 罗利克技术有限公司 2024-06-07 CN disclosed
EP-3990569-A1 NEW POLYMERIZABLE LIQUID CRYSTAL Rolic Technologies AG (CH) 2022-05-04 EP disclosed
CN-114026078-A Novel polymerizable liquid crystal 罗利克技术有限公司 2022-02-08 CN disclosed
US-9949970-B2 Synthesis of new benzothiazole derivatives as potential anti-tubercular agents COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2018-04-24 US disclosed
US-20160175303-A1 SYNTHESIS OF NEW BENZOTHIAZOLE DERIVATIVES AS POTENTIAL ANTI-TUBERCULAR AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2016-06-23 US disclosed
US-9273039-B2 Synthesis of new benzothiazole derivatives as potential anti-tubercular agents COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2016-03-01 US disclosed
US-20120095021-A1 SYNTHSIS OF NEW BENZOTHIAZOLE DERIVATIVES AS POTENTIAL ANTI-TUBERCULAR AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH 2012-04-19 US disclosed
WO-2008118790-A1 DIHYDROINDAZOLE COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2008-10-02 WO disclosed
US-20080234327-A1 DIHYDROINDAZOLE COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2008-09-25 US disclosed
US-20030072725-A1 Topical cosmetic agents containing 2-hydrazino-1,3 -heteroazoles HAARMANN & REIMER GMBH (DE) 2003-04-17 US disclosed
US-4732986-A Benzothiazole derivatives, processes for their preparation and pharmaceutical compositions containing these compounds LUDWIG HEUMANN & CO. GMBH (DE) 1988-03-22 US disclosed
EP-0160173-A1 Benzothiazole derivatives, processes for their production and medicaments containing them LUDWIG HEUMANN & CO GMBH (DE) 1985-11-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128268-A1 Use of 2-hydrazino-1,3-thiazoles as antioxidants GPX1, LPO, GPX4 NPC1 1079/4885RAB9A 3084/4885SMN1; SMN2 3373/4885
US-20160175303-A1 SYNTHESIS OF NEW BENZOTHIAZOLE DERIVATIVES AS POTENTIAL ANTI-TUBERCULAR AGENTS TST, TBCA, SDHA NPC1 1681/4885RAB9A 2476/4885SMN1; SMN2 4865/4885
US-20120095021-A1 SYNTHSIS OF NEW BENZOTHIAZOLE DERIVATIVES AS POTENTIAL ANTI-TUBERCULAR AGENTS TST, SDHB, SDHA NPC1 2311/4885RAB9A 4194/4885SMN1; SMN2 3952/4885
US-20080234327-A1 DIHYDROINDAZOLE COMPOUNDS USEFUL IN TREATING IRON DISORDERS FECH, SLC40A1, HAMP NPC1 539/4885RAB9A 1254/4885SMN1; SMN2 1839/4885
US-20030072725-A1 Topical cosmetic agents containing 2-hydrazino-1,3 -heteroazoles TYR, MITF, HDAC1 NPC1 2397/4885RAB9A 2330/4885SMN1; SMN2 4816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.